| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0735-1097(00)00911-6 |
| P698 | PubMed publication ID | 11079680 |
| P2093 | author name string | Burnett JC Jr | |
| Chen HH | |||
| Redfield MM | |||
| Jougasaki M | |||
| Grantham JA | |||
| Schirger JA | |||
| P2860 | cites work | Effects of brain natriuretic peptide on hemodynamics and renal function in dogs | Q68440691 |
| Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects | Q68602093 | ||
| Atrial natriuretic peptide elevation in congestive heart failure in the human | Q69987259 | ||
| The renal action of atrial natriuretic peptide during control of glomerular filtration | Q70010663 | ||
| Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction | Q70743359 | ||
| Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects | Q72163936 | ||
| The role of neutral endopeptidase in dogs with evolving congestive heart failure | Q72642247 | ||
| Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11 | Q24527775 | ||
| Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure | Q28297273 | ||
| Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases | Q46125243 | ||
| Isolation and identification of a high molecular weight brain natriuretic peptide in porcine cardiac atrium | Q47176394 | ||
| A new natriuretic peptide in porcine brain | Q48100804 | ||
| Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. | Q48477059 | ||
| Biochemical detection of left-ventricular systolic dysfunction. | Q48562979 | ||
| Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. | Q48829448 | ||
| Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. | Q48853320 | ||
| Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. | Q48889953 | ||
| Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure | Q68421475 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 1706-1712 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Subcutaneous administration of brain natriuretic peptide in experimental heart failure. | |
| P478 | volume | 36 |
| Q35987052 | BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases |
| Q30909922 | BNP and Heart Failure: Preclinical and Clinical Trial Data. |
| Q34369603 | BNP molecular forms and processing by the cardiac serine protease corin |
| Q33573360 | Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent |
| Q64276468 | Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease |
| Q42880557 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide |
| Q37399482 | Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension |
| Q40442907 | Current and future uses of nesiritide |
| Q37914972 | Diabetic neuropathy and heart failure: role of neuropeptides |
| Q51171144 | In vivo evaluation of the improved MCMS-0102 pacemaker with a rapid pacing mode for induction of experimental heart failure in animals. |
| Q37258795 | Insights into natriuretic peptides in heart failure: an update |
| Q48662099 | Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. |
| Q36129944 | Lebetin 2, a Snake Venom-Derived Natriuretic Peptide, Attenuates Acute Myocardial Ischemic Injury through the Modulation of Mitochondrial Permeability Transition Pore at the Time of Reperfusion |
| Q34891600 | Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model |
| Q37963837 | M-atrial natriuretic peptide: a novel antihypertensive protein therapy. |
| Q37108093 | Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure |
| Q37329891 | Modulation of cGMP in heart failure: a new therapeutic paradigm |
| Q26778333 | Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events |
| Q36794409 | Natriuretic peptides and therapeutic applications |
| Q36317213 | Natriuretic peptides: novel therapeutic targets in heart failure |
| Q80888699 | Neurohormonal Therapy for Congestive Heart Failure |
| Q37815438 | Novel natriuretic peptides: new compounds and new approaches |
| Q36564032 | Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide |
| Q37298343 | Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury |
| Q35790792 | Recent advances in natriuretic peptides in congestive heart failure |
| Q35106487 | Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics |
| Q37167803 | The role of natriuretic peptides in heart failure |
| Q81888133 | The role of natriuretic peptides in heart failure |
| Q35090364 | The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases |
| Q38220091 | cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications |
Search more.